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Abstract
Introduction: Surgery is currently the definitive treatment for early-stage breast cancer. However, the rate of
positive surgical margins remains unacceptably high. The human sodium iodide symporter (hNIS) is a naturally
occurring protein in human thyroid tissue, which enables cells to concentrate radionuclides. The hNIS has been
exploited to image and treat thyroid cancer. We therefore investigated the potential of a novel oncolytic vaccinia
virus GLV1h-153 engineered to express the hNIS gene for identifying positive surgical margins after tumor
resection via positron emission tomography (PET). Furthermore, we studied its role as an adjuvant therapeutic
agent in achieving local control of remaining tumors in an orthotopic breast cancer model.
Methods: GLV-1h153, a replication-competent vaccinia virus, was tested against breast cancer cell lines at various
multiplicities of infection (MOIs). Cytotoxicity and viral replication were determined. Mammary fat pad tumors were
generated in athymic nude mice. To determine the utility of GLV-1h153 in identifying positive surgical margins,
90% of the mammary fat pad tumors were surgically resected and subsequently injected with GLV-1h153 or
phosphate buffered saline (PBS) in the surgical wound. Serial Focus 120 microPET images were obtained six hours
post-tail vein injection of approximately 600 μCi of 124I-iodide.
Results: Viral infectivity, measured by green fluorescent protein (GFP) expression, was time- and concentration-
dependent. All cell lines showed less than 10% of cell survival five days after treatment at an MOI of 5. GLV-1h153
replicated efficiently in all cell lines with a peak titer of 27 million viral plaque forming units (PFU) ( <10,000-fold
increase from the initial viral dose ) by Day 4. Administration of GLV-1h153 into the surgical wound allowed
positive surgical margins to be identified via PET scanning. In vivo, mean volume of infected surgically resected
residual tumors four weeks after treatment was 14 mm3 versus 168 mm3 in untreated controls (P < 0.05).
Conclusions: This is the first study to our knowledge to demonstrate a novel vaccinia virus carrying hNIS as an
imaging tool in identifying positive surgical margins of breast cancers in an orthotopic murine model. Moreover,
our results suggest that GLV-1h153 is a promising therapeutic agent in achieving local control for positive surgical
margins in resected breast tumors.
Introduction
Surgery is currently the definitive treatment for early-
stage breast cancer. However, the rate of positive surgical
margins remains unacceptably high. Current techniques
for detecting positive margins include frozen sectioning,
touch prep cytology, gross evaluation, intra-operative
imaging with ultrasonography, and conventional histo-
pathology. Most meta-analyses report a positive margin
rate of 20 to 80% with current techniques. One report
showed that intra-operative assessment of gross margins
resulted in a 25% final margin positive rate [1]. Another
study from investigators at MD Anderson showed that a
combination of intra-operative gross margin assessment,
specimen radiography and frozen section still resulted in
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a final positive margin rate of 20% [2]. Other groups have
compared radio-guided occult lesion localization with
wire localization, yielding high positive margin rates of
83% and 56%, respectively [3]. All current techniques
have limitations and to our knowledge there are no data
to support a statement that any strategy is superior to
another. Overall, the literature still demonstrates that up
to 40% of the patients return to the operating table for a
re-excision despite the best efforts for breast-conserving
surgery [4].
Oncolytic viral therapies have shown great success in
preclinical and clinical testing as a novel cancer treatment
modality [5]. Oncolytic viral therapy relies on the ability of
genetically engineered viruses to specifically infect, repli-
cate within and ultimately lyse tumor cells [6]. Specifically,
Yu et al. showed via low light and fluorescence imaging
how vaccinia virus gained entry and replicated only in the
tumor tissue without causing viremia in live animals [7].
Moreover, the safety of using vaccinia viruses in humans
has been well demonstrated during the eradication of
smallpox virus [8].
Recently, a novel vaccinia virus, GLV-1h153, has been
shown to be simultaneously safe, diagnostic and therapeu-
tic for the use against several human cancers, including
anaplastic thyroid and pancreatic cancer in animal models
[9,10]. Here, we report the potential of this vaccinia virus
carrying the human sodium iodide symporter (hNIS) in
identifying positive surgical margins in an orthotopic
breast cancer model. Moreover, we tested whether GLV-
1h153 can be used as adjuvant therapy for positive




Human TNBC cell lines HCC38 and MDA-MB-468
were obtained from the ATCC (American Type Culture
Collection, Manassas, VA USA). Human MDA-MB-231
breast carcinoma cells stably expressing mCherry fluor-
escent protein were kindly provided by Dr. Koblinski
from Northwestern University. HCC38 cells were main-
tained in RPMI (supplemented with Hepes, L-glutamine,
sodium pyruvate, final concentrations 10, 2, 1 mM,
respectively, and with 1.5 g/L sodium bicarbonate, 4.5 g/
L glucose). MDA-MB-231 and MDA-MB-468 cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 containing 5% FBS, 100 IU/mL penicillin/
streptomycin, 1 mM sodium pyruvate, 2X nonessential
amino acids. Medium for MDA-MB-231 mCherry cells
was supplemented with 1 μg/mL blasticidin (Sigma-
Aldrich, St. Louis, MO USA}). CV-1 cells for viral
plaque assay were maintained in Minimum Essential
Medium (MEM). All media were supplemented with
10% fetal calf serum with penicillin (100,000 U/L) and
streptomycin (100 mg/L). All cell lines were grown in a
5% CO2 humidified incubator at 37°C.
Virus
GLV-1h153 is a replication-competent, recombinant
vaccinia virus based on the vaccinia virus LIVP strain
(Lister strain from the Institute for Research on Virus
Preparations, Moscow, Russia) and its construction has
been described previously [10]. Pertinent to our study,
GLV-1h153 expresses hNIS and GFP. The genotype of
hNIS-expressing VACV GLV-1h153 was verified by PCR
and sequencing.
Green fluorescent protein expression
Cells were plated at 2 × 104 per well in 96-well plates in
200 μL of media. After overnight incubation, cells were
exposed to GLV-1h153 at a multiplicity of infection
(MOI) of 0.1, 1.0 or 5.0. Cells were examined using
fluorescence-inverted microscopy (Nikon Eclipse TE300,
Nikon, Japan) to detect GFP expression at set time
intervals (24, 48, 72 hours).
Cytotoxicity assays
Cells were plated at 3 × 104 cells per well in 24-well
plates and incubated overnight. GLV-1h153 was added
to each well at varying MOIs of 0, 0.1, 1.0 and 5.0. Viral
cytotoxicity was tested using a lactate dehydrogenase
(LDH) assay daily. Cells were washed with phosphate
buffered saline (PBS) once and then lysed with Triton X-
100 (1.35%, Sigma, St. Louis, MO, USA). The intracellular
LDH release following lysis was subsequently measured
with a Cytotox 96 kit (Promega, Madison, WI, USA) on a
spectrophotometer (EL321e, Bio-Tek Instruments,
Winooski, VT USA}) at 490 nm. Results were expressed as
the percentage of surviving cells, calculated as the LDH
release of infected samples compared to negative control
(cells without virus). All samples were analyzed in
triplicate.
Viral plaque assay
After infection of cells with virus and prior to daily cyto-
toxicity assay, supernatants of each infected well were
collected daily for five days and immediately frozen at -80°
C for storage. Serial dilutions of each supernatant samples
were made to perform standard viral plaque assays on
confluent CV-1 culture plates. All samples were measured
in triplicate and the results averaged.
Xenograft model and surgical resection
All mice were cared for and maintained in accordance
with animal welfare regulations under a protocol approved
by the Institutional Animal Care and Use Committee
(IACUC) of Memorial Sloan-Kettering Cancer Center
(MSKCC). Orthotopic mammary fat pad xenografts were
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generated in female athymic nude mice aged 8 to 10
weeks. Mice were anesthetized with 1 to 3% isoflurane and
injected with 100 μL of 5 × 106 MDA-MB-231 mCherry-
expressing cells suspended in 50% matrigel (BD Bios-
ciences, Franklin Lakes, NJ, USA) into the mammary fat
pad. After two weeks of tumor formation, 90% of each
tumor was surgically resected from the mammary fat pad
so that only a small margin of tumor (< 5 mm in the
largest dimension) remained. Subsequently, GLV-1h153
(1 × 106 PFU)/50 μL PBS) or 50 μL of PBS for controls
were injected into the surgical wound and the wound was
closed with a stapler.
In vivo fluorescent imaging (Maestro)
In vivo fluorescent images were obtained with the CRi
Maestro system (Cambridge Research and Instrumenta-
tion, Woburn, MA, USA) using the appropriate filter set
(excitation = 575 to 605 nm, emission = 645 nm long-pass
filter). After each image was obtained, it was spectrally
unmixed to remove the background fluorescence and
overlay images were produced.
In vivo PET imaging
Control and GLV1h153-treated groups of three animals
bearing MDA-MB-231 tagged with mCherry orthotopic
mammary fat pad tumors were injected with 600 μCi
of 124I via tail vein injection four days after surgical resec-
tion. Six hours after radiotracer administration, three-
dimensional list-mode data were acquired. Imaging
was performed using a Focus 120 microPET dedicated
small animal PET scanner (Concorde Microsystems Inc,
Knoxville, TN, USA). The count rates in the reconstructed
images were converted to activity concentration (%ID/g)
using a system calibration factor (MB q/mL per cps/voxel)
derived from imaging of a mouse size phantom filled with
a uniform aqueous solution of 18F. Image analysis was
performed using ASIPro software (Siemns Medical Solu-
tions USA, Inc. Malvern, PA USA).
Treatment of positive surgical margin in an orthotopic
TNBC xenograft model
A total of 14 female athymic nude mice (Harlan Labora-
tories, Indianapolis, IN USA) aged six to eight weeks were
injected with 5 × 106 MDA-MB-231-mCherry cells unilat-
erally into the fourth mammary fat pad. Four weeks after
tumor inoculation, surgical resection of tumors was
performed (as described above) and mice were rando-
mized into two groups. Xenografts were treated with
GLV-1h153 (1 × 106 PFU/50 μL PBS) or 50 μL of PBS for
controls into the surgical wound at the time of resection.
The size of the residual tumor created at the positive mar-
gins (length and width) was recorded immediately after
resection and one month after treatment with GLV-
1h153. Tumor volumes were calculated by the equation,
V (mm3) = (4/3)*(π)*((a/2)2*(b/2)) where ‘a’ is the smallest
diameter and ‘b’ the largest diameter. Four weeks after
treatment, mice were sacrificed and tumors were har-
vested and embedded in paraffin for histological analysis.
Microscopic imaging
A Lumar V.12 stereo-microscope (Carl-Zeiss Oberkochen,
Germany) with 1.2x objective was used to image surgically
resected tumors that were excised from the animal at the
end of the study using bright field and fluorescent
techniques.
Fixation, tissue preparation and H&E staining
To prepare tissue sections for H&E staining, tissues were
fixed with 4% paraformaldehyde in PBS overnight at 4°C,
washed in 70% ethanol and processed for paraffin embed-
ding per the standard protocol of the Molecular Cytology
Core Facility of MSKCC. Five-micron sections were cut
serially from paraffin-embedded tumor tissue blocks.
Slides were air dried and baked at 60°C for one hour. We
confirmed that all margins were evaluated histologically
by a board-certified pathologist at MSKCC.
Statistical analysis
All results were reported as means with standard errors.
The significance of differences between different groups
was determined using the Student’s t test (Excel 2007;
Microsoft, Redmond, WA, USA). A P-value < 0.05 was
considered significant.
Results
GLV-1h153 demonstrated time- and dose-dependent
infectivity in cell cultures
Viral infectivity and GFP expression were assessed 24, 36
and 72 hours after viral infection at an MOI of 0.1, 1 or 5
by fluorescence microscopy (Figure 1A). GFP expression
confirmed viral infection by 24 hours in all cell lines and
was proportional to viral concentration. As depicted in
Figure 1B, viral infection was time-dependent, increasing
from Day 1 to Day 3 and decreasing by Day 6 as cell death
occurred in all cell lines.
GLV-1h153 induced cell death in a dose-dependent
fashion in TNBC lines in vitro
GLV-1h153 killed all TNBC cell lines effectively in a
dose-dependent fashion (Figure 2A). At an MOI of 5,
GLV-1h153 achieved near-complete cell kill in all cell
lines by Day 5. At lower viral concentrations (MOI 1),
there was still significant viral potency to MDA-MB-
468 and HCC38 with greater than 92% and 67% cyto-
toxicity effect, respectively. Survival curves indicate
time-dependent cell kill in all cell lines as expected
from the results of the viral infectivity assay and GFP
expression.
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Figure 1 Cell lines MDA-MB-468, MDA-MB-231 and HCC38 show sensitivity to infection with GLV-1h153. A. Viral infection was
concentration-dependent as shown by increasing number of GFP-expressing cells. B. Viral infection demonstrated to be time-dependent. GFP
expression increased early after infection as shown from Day 1 to Day 3, but then decreased when cell death occurred (by Day 6). Illustrated
were images from infection at an MOI of 1.
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GLV-1h153 replicates efficiently in all TNBC cell lines
Standard viral plaque assays were performed to assess
for viral replication in TNBC cells. After infection with
GLV-1h153 at an MOI of 1, all TNBC cell lines allowed
efficient viral replication (Figure 2B). For all cell lines,
the viral titer exhibited up to a 4-log, or 10,000-fold,
increase from the initial viral dose only 96 hours after
infection. MDA-MB-468 supported the highest viral
titer, with a peak titer of 2.7 × 107\PFU/mL four days
after infection.
In vivo visualization of positive surgical margins with
fluorescent imaging
Ninety percent of the tumors were surgically resected
from the mammary fat pad, so that only a small remnant
of tumor (< 5 mm in the largest dimension) remained
(Figure 3A). To ensure that a positive margin was pre-
sent after surgical resection of the mammary fat pad
tumors, mCherry expression was assessed four days later
by Maestro™ fluorescence imaging (PerkinElmer,
Waltham, MA USA). In vivo fluorescence imaging
demonstrated minimal mCherry signal localized to the
surgical margin of the xenografts in all surgically
resected tumors (Figure 3B).
GLV-1h153 identifies positive surgical margins via hNIS-
mediated radioiodine uptake by PET
In vivo, positive surgical margins of infected mammary
fat pad tumor wounds treated at the time of resection
with GLV-1h153 were successfully visualized by PET
imaging. All GLV-1h153-injected animals’ wounds
showed accumulation of 124I-iodine radioactivity loca-
lized to the tumors (Figure 4A) compared with unin-
fected controls. Positive margins were visualized as early
as six hours after radiotracer injection in all three
infected animals. Average radioiodine uptake in the 3
GLV-1h153-infected mice with positive margins was 2.5
± 0.30% ID/g six hours post radiotracer injection.
Figure 2 GLV-1h153 kills and replicated efficiently in breast cancer cell lines in vitro. A. GLV-1h153 kills breast cancer cells in a dose-
dependent fashion. Cytotoxicity data of cell lines MDA-MB-231, MDA-MB-468 and HCC38 showed less than 10% viable cells after five days of
infection at an MOI of 5. Multiplicity of infection (MOI) = plaque-forming units/cell. Experiment was performed in triplicates. B. GLV-1h153
replicated efficiently in all breast cancer cell lines. All cell lines supported viral replication as assessed by the viral plaque assay. Results
demonstrated that in cell line MDA-MB-468, GLV-1h153 reached the highest titer of 2.7 × 107 PFU after 96 hours of infection, representing over
a 10,000-fold increase in copy numbers from the initial viral dose. The experiment was performed in triplicates.
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GLV-1h153 effectively prevents progression of residual
tumor at surgical margins in vivo
5In vivo, positive surgical margins of mammary fat pad
tumor were treated at the time of resection with GLV-
1h153 or PBS. Infected residual tumors were successfully
controlled with viral therapy while uninfected control
tumors continued to grow over the course of a month
after tumor resection. GLV-1h153-injected positive
margins averaged a size of 14 mm3 four weeks after treat-
ment compared to 168 mm3 in uninfected controls
(Figure 5). All mice tolerated treatment without any com-
plications or side effects. Fifty percent (three out of the
six) of treated mice demonstrated complete regression of
residual tumor. H&E staining of the three remaining
Figure 3 Surgical margins of breast cancer after resection can be detected via mCherry fluorescence imaging in vivo. A. Photographs of
an animal pre- and post-surgical resection of the mammary fat pad tumor shown in upper panel. Tumor is outlined by dotted line. B. Bottom
panel shows a photograph after surgical resection and infection with a closed wound. To the right is shown a mCherry Maestro fluorescence
image to confirm that a positive margin was present prior to PET imaging.
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treated margins showed necrosis and fibrosis and only a
few viable tumor cells present. Sections of uninfected
positive margins, in contrast, demonstrated invasive car-
cinoma of high histologic grade associated with lympho-
vascular invasion as shown by tumor emboli within the
dermal lymphatics. Tumor cells exhibited a high degree
of nuclear pleomorphism with large nuclei, irregular
chromatin and conspicuous nucleoli.
GLV1h153 can be detected in GPF-expressing cells in
positive surgical margins
Four weeks after viral infection with GLV-1h153, resected
surgical margins were imaged to confirm if viral particles
could be detected within tumor margins. GFP-positive
cells were visible within all three remaining tumors at the
surgical margin after treatment. Virus-infected tumor mar-
gins both expressed mCherry and GFP in contrast to unin-
fected tumors, which only expressed mCherry (Figure 6).
H&E staining of tissues from control tumors showed
malignant cells consistent with TNBC compared to large
areas of fibrosis and necrosis in GLV-1h153-treated
tumors without any viable cancer cells (Figure 7).
Discussion
Surgical resection is currently the mainstay of treatment
for early-stage breast cancer, with the goal of obtaining
negative surgical margins. With the advent and accep-
tance of breast-conserving therapy and radiation, the
definition of a safe surgical margin and the indications and
extent of re-excision have been the subject of frequent
debate and study. A 20-year follow-up prospective rando-
mized clinical trial conducted by the National Surgical
Adjuvant Breast and Bowel project demonstrated equiva-
lent overall and disease-free survival in the treatment of
early stage breast cancer by mastectomy compared to
breast conservation therapy and radiation. However, high
Figure 4 GLV-1h153 can identify positive surgical margins of breast cancer after resection via hNIS-mediated radio-uptake. A. microPET
images shown six hours after radiotracer injection of all three infected animals after surgical resection. B. Three-dimensional (3D) view of PET
images of one infected animal at the surgical margin.
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rates of positive surgical margins ranging from 20 to 80%
remain a major issue surrounding conservative resection
[11]. It is now widely accepted in the literature that obtain-
ing negative surgical margins is an important predictor for
local recurrence after wide excision of invasive breast can-
cer [12-15]. Moreover, studies have shown that patients
with positive surgical margins have a higher risk of distant
failure after five years [16,17]. While wider margins of
resection increase the likelihood of obtaining negative
margins, it comes at an increasing financial, cosmetic and
psychological cost to the patient. Furthermore, obtaining
wide margins is not always feasible if a prior excision
leaves no residual breast tissue behind. The challenge is
to remove enough breast tissue to prevent recurrence,
while saving an adequate breast volume to yield satisfactory
cosmetic results.
Presently the intra-operative assessment of margins
include gross examination of the specimen by the oper-
ating surgeon and the pathologist for residual tumor,
ultrasound, radiography of the specimen, frozen section,
touch prep cytology and sampling of tumor cavity margins.
Unfortunately, all current methods to determine margin
status have some technical or practical limitation [1,18].
Thus, innovative techniques of identifying positive surgi-
cal margins are needed to decrease the high rate of
re-operation for patients with breast cancer.
The historical use of vaccinia as a vaccine for smallpox
demonstrated its safety when it was given to millions of
people, with a very low toxicity rate of less than 1%. More-
over, specific deletions within the genome of oncolytic
viruses allow for more specific tumor targeting. In the case
of GLV-1h153, inactivation of the thymidine kinase (TK)
gene, for example, makes the replication more dependent
on host cell TK for deoxyribonucleotide synthesis, which
may allow for increased selectivity of viral replication for
malignant neoplasms [12,13]. Second, the TK mutation
may attenuate the ability of vaccinia to replicate within
normal tissues, making it safer for clinical application [14].
Figure 5 GLV-1h153 effectively prevents progression of residual breast tumor at surgical margins in vivo. Residual tumors at surgical
margins of control mice grew from an average size of 25 mm3 to 169 mm3 (over a four-fold increase in tumor volume) compared to the
average tumor size of treated mice which regressed from 20 mm3 to 14 mm3 in infected surgical margins within four weeks of treatment after
resection (P < 0.05). Three out of six of the treated mice demonstrated complete regression of residual tumor.
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Other anti-apoptotic genes, such SPI-1 and SPI-2 [16],
have also been shown to enable preferential viral repli-
cation selectively in tumor tissues, allowing for more
targeted therapy. In our studies, we showed how vacci-
nia specifically targets tumors without affecting the
surrounding organs. For example, when the parent
virus (GLV-1h68) was used to treat anaplastic thyroid
cancer xenografts in vivo, virus biodistribution in mice
10 days after a single viral intratumoral injection
showed high viral recovery in tumors, but only mini-
mal recovery in other organs [19].
For our in vitro and xenograft model, we chose to
work with a TNBC model. While this work is relevant
to the treatment and imaging of receptor-positive breast
cancer as well, TNBCs represent a subset of invasive
breast cancers whose lack of receptor targets for hormo-
nal therapy confer an even greater dependency upon
complete, margin-free surgical resection for patient sur-
vival. In our study, we demonstrated the ability of a new
oncolytic vaccinia virus engineered to express hNIS to
identify positive surgical margins of resected mammary
fat pad tumors in an orthotopic breast cancer model via
Figure 6 GPF-expressing malignant cells are detected in positive surgical margins with fluorescent microscopy. Uninfected control
tumors (treated with PBS) express mCherry only and no GFP signal (top panel). Bottom panel represents an infected remaining tumor margin
four weeks after treatment with GLV-1h153. The tumor expresses mCherry as well as GPF signal.
Figure 7 H&E slides of untreated and treated positive surgical margins. Positive-margin controls (left) show malignant cells with large
nuclei and irregular chromatin. Treated positive margins H&E slides (right) represent tissue margins four weeks after treatment with GLV-1h153.
Large areas of fibrosis and necrosis can be seen without any viable cancer cells.
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I124-iodine PET imaging while providing concurrent
local control to residual tumors.
In vivo, mammary fat pad tumors generated from
mCherry-tagged MDA-MB-231 cells that were incom-
pletely resected and treated with GLV-1h153 prior to
wound closure resulted in visualization of the residual
tumor margin by I124-iodine PET scanning. Uninfected
controls did not show any evidence of radiotracer accumu-
lation and could not be imaged via PET imaging. This was
a proof-of-concept study with the purpose of assessing the
ability of the virus to serve as an effective visible marker of
a positive surgical margin. To adequately mimic resection
of early-stage human malignancy, this model will even-
tually need to be applied to microscopic margins. Other
research groups have used different viral vectors, such as
adenovirus, to increase hNIS expression and allow for
radionuclide uptake in prostate and medullary thyroid
cancer [20-22]. But to our knowledge, this is the first
study to show increase in hNIS expression and accumula-
tion of radioiodine in a TNBC model. One of the largest
studies showed that approximately 70% of breast cancers
(hormone receptor positive as well as TNBC) [23] express
hNIS, but smaller series have only shown no greater than
34% hNIS expression [24]. Such an expression level, how-
ever, has not been proven to be sufficient for therapeutic
radioiodine accumulation.
In our study, all animals infected with GLV-1h153
increased the expression of hNIS, required to concentrate
radioactive iodine for imaging. Moreover, our study
showed that GLV-1h153 can directly act as an adjuvant
therapeutic agent and treat residual tumors at the surgical
margin identified on imaging. Our results demonstrated a
significant difference in tumor volume between infected
and uninfected residual tumors four weeks after a single
virus injection into the surgical wound. In addition, in
remaining infected margins, the GFP signal was still pre-
sent by fluorescence microscopy four weeks after treat-
ment. This result has two important implications. First,
detection of GFP in cells indicates active viral infection
and thus possible continued treatment. Second, the pre-
sence of GFP signal can also be used as a diagnostic tool
in the clinical setting in detection of residual disease. Alto-
gether, the utility of this novel virus in the present work is
its ability to provide early and direct visualization of resi-
dual tumor in the resection bed while simultaneously
treating the remnant tumor cells. In addition, PET ima-
ging may allow for noninvasive detection of viral distribu-
tion. The tracking of viral delivery could give clinicians the
ability to correlate therapeutic efficacy and monitor poten-
tial viral toxicity. In the clinical setting, one potential
approach of the virus would be used in a two-step proce-
dure: the virus would be applied to the surgical wound at
the time of resection followed by multiple post-resection
I124-iodine PET scans (at two- to four-month intervals).
The expected I124-iodine tumor uptake would provide a
metric of residual disease post-resection and the difference
in uptake between subsequent scans would give a metric
of therapeutic response. Therefore, GLV-1h153 can be
utilized potentially as a therapeutic agent and predictor of
therapeutic response.
There are both technical and biological limitations of the
method proposed for detection of microscopic and resi-
dual disease. The former include PET scanner sensitivity
and, most importantly, resolution. The latter include spe-
cific and non-specific uptake of radioiodide. As detailed
above, and as largely determined by the spatial resolution
of the scanner, the minimum number of cells detectable
by PET in a cluster is approximately 100 million. Low
tumor-specific uptake of the radiotracer and non-specific
uptake by normal tissues decrease the tumor-to-normal
tissue ratio and thus further degrade the detectability of
microscopic/residual disease. For example, significant
uptake of fluorine-18-labeled fluorodeoxyglucose (FDG),
the most widely used oncologic PET tracer, occurs in non-
malignant inflammatory cells, such as macrophages and
neutrophils, reducing the specificity of FDG PET for
malignant disease. An important potential advantage of
our method is improved specificity. Radioiodide is signi-
ficantly concentrated only in the thyroid, salivary glands,
stomach and lactating breast; it is otherwise rapidly cleared
from the body. GLV1h153 treatment plus I124-iodine thus
has the potential to yield highly specific as well as sensitive
PET images of malignant disease.
Conclusions
In conclusion, this pilot study demonstrates that a
mutated vaccinia virus expressing hNIS can identify a osi-
tive surgical margin in an orthotopic breast cancer model
and effectively treat remaining tumors in vivo. Positive
surgical margins remain a major issue despite best current
efforts. Therefore, our data strongly encourage the conti-
nued investigation of GLV-1h153 as a novel imaging tool
for identifying positive surgical margins and adjuvant
therapeutic agents in the treatment of breast cancer.
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